Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04362137 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 432
- Enrollment target
NCT04362137 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 432 participants.
The verdict
NCT04362137, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 432 participants
- Enrollment target
Study Summary
This was a randomized, double-blind, placebo-controlled, 29-day, multicenter study to assess the efficacy and safety of ruxolitinib + standard-of-care (SoC) therapy, compared with placebo + SoC therapy, in patients aged ≥12 years with COVID-19 disease.
Interventions
- DRUG Placebo
- DRUG Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 432 participants |
| Start Date | 2020-05-02 |
| Est. Completion | 2020-10-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04362137
The ClinicalTrials.gov registry entry for NCT04362137 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 432 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04362137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04362137 about?
NCT04362137 is a clinical study titled "Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm". This was a randomized, double-blind, placebo-controlled, 29-day, multicenter study to assess the efficacy and safety of ruxolitinib + standard-of-care (SoC) therapy, compared with placebo + SoC therapy, in patients aged ≥12 years with COVID-19 disease.
What is the current status of trial NCT04362137?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 432 participants. The study started on 2020-05-02. Estimated completion is 2020-10-17.
What interventions are being tested in trial NCT04362137?
The interventions under investigation include: Placebo (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT04362137?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.